--- title: "Health In Tech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 8.772 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286466752.md" datetime: "2026-05-14T20:50:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286466752.md) - [en](https://longbridge.com/en/news/286466752.md) - [zh-HK](https://longbridge.com/zh-HK/news/286466752.md) --- # Health In Tech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 8.772 M Revenue: As of FY2026 Q1, the actual value is USD 8.772 M, beating the estimate of USD 7.464 M. EPS: As of FY2026 Q1, the actual value is USD -0.03. EBIT: As of FY2026 Q1, the actual value is USD -2.226 M. #### Segment Revenue (Operational Categories) - **Revenues from underwriting modeling (ICE)**: For the three months ended March 31, 2026, revenues were $1,468,814 (16.7% of total revenues), a decrease of -37.6% from $2,351,984 (29.3% of total revenues) for the same period in 2025, representing a year-over-year change of -$883,170. - **Revenues from fees (SMR)**: Revenues increased by 29.0% to $7,302,832 (83.3% of total revenues) for the three months ended March 31, 2026, compared to $5,663,000 (70.7% of total revenues) for the same period in 2025, reflecting a year-over-year change of $1,639,832. - **Program and platform management fees (within SMR)**: These fees decreased by -49.7% to $2,850,676 (32.5% of total revenues) for the three months ended March 31, 2026, from $5,663,000 (70.7% of total revenues) in the prior year, a year-over-year change of -$2,812,324. - **Self-funded plan administration fees (within SMR)**: These fees totaled $4,452,156 (50.8% of total revenues) for the three months ended March 31, 2026, with no comparable revenue in 2025 as this service launched on January 1, 2026. #### Operational Metrics - **Gross Profit**: The gross profit was $4,509,399 for the three months ended March 31, 2026, down from $5,355,399 for the same period in 2025. - **Gross Margin**: The gross margin was 51.4% for the three months ended March 31, 2026, a decrease from 66.8% for the same period in 2025. - **Cost of Revenues**: Cost of revenues increased by $1,602,662 to $4,262,247 (48.6% of total revenues) for the three months ended March 31, 2026, compared to $2,659,585 (33.2% of total revenues) in 2025, primarily due to costs associated with new pre-designed plan offerings. - **Sales and Marketing Expenses**: These expenses rose by $1,201,346 to $2,291,601 (26.1% of total revenues) for the three months ended March 31, 2026, from $1,090,255 (13.6% of total revenues) in 2025, mainly due to increased sales distribution fees. - **General and Administrative Expenses**: General and administrative expenses increased by $208,793 to $3,455,558 (39.4% of total revenues) for the three months ended March 31, 2026, from $3,246,765 (40.5% of total revenues) in 2025, largely due to public company expenses, partially offset by improved operating leverage. - **Research and Development Expenses**: These expenses increased by $382,674 to $920,395 (10.5% of total revenues) for the three months ended March 31, 2026, from $537,721 (6.7% of total revenues) in 2025, driven by continued focus on developing new platform functionalities. - **Net Income (Loss)**: Health In Tech, Inc. reported a net loss of -$1,588,281 (-18.1% of total revenues) for the three months ended March 31, 2026, a decline from a net income of $498,592 (6.3% of total revenues) in the prior year period. - **Adjusted EBITDA**: Adjusted EBITDA was -$1,288,515 (-14.7% of total revenues) for the three months ended March 31, 2026, a decrease of -$2,516,726 from $1,228,211 (15.3% of total revenues) in 2025, mainly due to plan administrative service costs and distribution fees not incurred previously. #### Cash Flow - **Operating Activities**: Cash flow from operating activities was -$3,319,247 for the three months ended March 31, 2026, compared to $527,353 for the same period in 2025. - **Investing Activities**: Cash flow used in investing activities was -$362,131 for the three months ended March 31, 2026, an improvement from -$703,475 in 2025. - **Financing Activities**: Cash flow from financing activities was $6,336,832 for the three months ended March 31, 2026, significantly higher than -$98,089 in 2025. #### Unique Metrics - **Contracted Revenue**: As of March 31, 2026, Health In Tech, Inc. had $22.9 million in contracted revenue expected to be recognized during the remaining three quarters of 2026. - **Platform Placed Plan Value (PPPV)**: The company’s platform placed $82.0 million of self-funded stop-loss plans in the first quarter of 2026. #### Future Outlook and Strategy Health In Tech, Inc. plans to allocate net proceeds from its recent PIPE financing towards expanding sales distribution, advancing technology development, and for general corporate purposes. The company’s growth strategy focuses on broadening its partner network, collaborating with more insurance carriers to introduce new products, and continuously investing in technology and innovation to enhance automation and operational efficiency. SMR has shifted to offering pre-designed self-funded plans, and ICE is considering offering standalone underwriting services in the future. ### Related Stocks - [HIT.US](https://longbridge.com/en/quote/HIT.US.md) ## Related News & Research - [Health In Tech Showcases AI Platform in Investor Presentation](https://longbridge.com/en/news/286330879.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Autohome Inc. to Announce First Quarter 2026 Financial Results on May 28, 2026 | ATHM Stock News](https://longbridge.com/en/news/286390966.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)